Sovaprevir
In 2002, Achillion initiated a program to discover and develop drug candidates effective against the hepatitis C virus. Since that time, Achillion has successfully leveraged its expertise in medicinal chemistry and virology to develop its NS4A antagonist series. Achillion also used this expertise in a proprietary program against a more traditional and proven target, NS3 protease. Its lead Phase 2 drug candidate from this program is sovaprevir, formerly ACH-1625. more
ACH-3102
One of Achillion's most promising HCV compound in development is ACH-3102, a potent second generation NS5A inhibitor which Achillion discovered in 2011 and nominated as a clinical candidate that same year. Because of the synergy noted in vitro between NS5A inhibitors and NS3 protease inhibitors, Achillion rapidly advanced ACH-3102 through preclinical development and IND-enabling studies. With an improved resistance profile Achillion is currently evaluating ACH-3102 in a Phase 2 clinical trial evaluating 12 weeks treatment for genotype 1b HCV. more
ACH-2684
In its third proprietary program against hepatitis C infection, Achillion nominated ACH-2684, a compound that demonstrates excellent potency in the low pico-molar range, as well as good pharmacokinetic and safety profiles in preclinical studies. The potency and virology profile of ACH-2684 demonstrates that it very effectively suppresses a broad range of natural variants of the hepatitis C virus, and may be effective in prevention and treatment of emerging resistant variants. more
ACH-702
Achillion discovered ACH-702, a compound that was out-licensed for the treatment of opthalmic bacterial infections. ACH-702 has a novel target profile against bacterial DNA replication enzymes, and potent broad-spectrum bactericidal activity, characteristics that indicate it may play an important role in the fight against drug-resistant bacteria. more
Discovery Programs
While pursuing the development of its lead programs in the HIV, HCV and antibacterial areas, Achillion continues to engage in the preclinical development of earlier-stage drug candidates. more
Discovery Technologies
Achillion intends to continue applying its deep understanding of virology, microbiology and synthetic chemistry to expand its product candidate portfolio. From early lead identification through clinical candidate selection, Achillion has coupled its knowledge base in genomic replication targets with an integrated drug discovery infrastructure to aid in the rapid advancement of its discovery programs. more
